trial

Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women

NCTId NCT01041092
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 34 (actual)
Sponsored by Fundació Sant Joan de Déu
Primary completion 2009-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
34 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2004-06
Primary completion
2009-12
Eligibility
FEMALE · 40 Years

Interventions & indications

Drugs
Raloxifene

Sponsors

Fundació Sant Joan de DéuLead Sponsor

Sites

1 total
Esplugues de Llobregat, Spain

Facts & assertions

4 sourced
Enrollment
34
Phase
PHASE4
Primary Completion Date
2009-12
Status
COMPLETED
relationships
The graph out of here
drug
Raloxifene
drug
lead_sponsor
Fundació Sant Joan de Déu
company
indication
Schizophrenia
indication
Schizophrenia
indication